Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma

Liu, Xiaohong; Cao, Dedong; Liu, Hui; Dong, Ke; Ke, Xiaokang; Xu, Ximing

doi:10.2147/cmar.s369086

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to treatment, surgery, radiation, and chemotherapy were found to be associated with a lower risk of OS and CSS in the first primary NHL. A study by Liu et al suggested that chemotherapy and surgery are beneficial to patients with primary small intestinal DLBCL [ 30 ]. Chemotherapy and radiation therapy showed a significant association with OS and CSS in primary gastric DLBCL patients [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study

Yu,

Zhang,

Zhong

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background The aim of this study was to investigate patient survival and factors associated with survival in second primary non-Hodgkin lymphoma (NHL) compared with the first primary NHL. Methods The retrospective cohort study used data from the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2014. Demographic characteristics, histological types, Ann Arbor stage, and treatment information were collected. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for factors associated with overall survival (OS) and cancer-specific survival (CSS) in the first and second primary NHLs. Results Of 318,168 cases followed for 5 years, 299,248 patients developed the first primary NHL and 18,920 patients developed the second primary NHL. This study identified a rising incidence of first and second primary NHL from 2000 to 2014. For the second primary NHL, the OS risk was higher when compared to the first primary NHL (HR: 1.13, 95% CI: 1.11 to 1.15, P <0.001). Risk factors that negatively affected OS in the first primary NHL included being male, over 40 years of age, certain marital statuses, specific histological types, and advanced disease stages. In contrast, being of White race and having histological types such as Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and mantle B-cell NHL were associated with better OS outcomes. Treatments like surgery, radiation therapy, and chemotherapy were associated with a lower risk of OS and CSS in the first primary NHL. For the second primary NHL, the detrimental risk factors were similar but also included being over the age of 60. Certain histological types showed a lower OS risk relative to diffuse Large B-cell Lymphoma (DLBCL). While surgery and chemotherapy were beneficial for OS, radiation therapy did not improve survival in second primary NHL cases. Notably, undergoing chemotherapy for the first primary cancer increased the OS risk in the second primary NHL, whereas surgery and radiation seemed to offer a protective effect against OS risk in the second primary NHL (all P <0.05). Conclusion Our findings emphasize the need for tailored strategies in managing the second primary NHL, given the distinct survival patterns and risk factor profiles compared to the first primary NHL. Future research should aim to further elucidate these differences to improve prognosis and treatment approaches for second primary NHL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study

Yu,

Zhang,

Zhong

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Primary gastric DLBCL is the most common location of DLBCL in the gastrointestinal tract [8]. Several staging systems have been developed over the past decades to improve prognostic stratification of gastrointestinal lymphoma; unfortunately, there has been no accepted standard till now [9][10][11]. In this study, we involved the information of 7200 patients diagnosed as PG-DLBCL from the large dataset SEER, and then, collected 1204 cases to construct a novel predictive nomogram and validate it with a 512 patient internal validation cohort.…”

Section: Discussionmentioning

confidence: 99%

A Novel Prognostic Model for Patients with Primary Gastric Diffuse Large B-Cell Lymphoma

Lin

Ruan

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objectives. Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is a common phenotype of extranodal non-Hodgkin’s lymphoma (NHL). This research aims to identify a model for predicting overall survival (OS) and cancer-specific survival (CSS) in PG-DLBCL. Methods. A total of 1716 patients diagnosed with PG-DLBCL between 1975 and 2017 were obtained from the SEER database and further randomly divided into the training and validating cohorts at a ratio of 7 : 3. Univariate and multivariate cox analyses were conducted to determine significant variables for the construction of nomogram. The performance of the model was then assessed by the concordance index (C-index), the calibration plot, and the area under the receiver operating characteristic (ROC) curve (AUC). Results. Multivariate analysis revealed that age, race, insurance status, Ann Arbor stage, marital status, chemotherapy, and radiation therapy all showed a significant association with OS and CSS. These characteristics were applied to build a nomogram. In the training cohort, the discrimination of nomogram for OS and CSS prediction was excellent (C-index = 0.764, 95% CI, 0.744–0.784 and C-index = 0.756, 95% CI, 0.732–0.780). The AUC of the nomogram for predicting 3- and 5-year OS was 0.779 and 0.784 and CSS was 0.765 and 0.772. Similar results were also observed in the internal validation set. Conclusions. We have successfully established a novel nomogram for predicting OS and CSS in PG-DLBCL patients with good accuracy, which can help physicians to quickly and accurately complete the evaluation of survival probability, risk stratification, and therapeutic strategy at diagnosis.

show abstract

Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL

Lai,

Zhao,

Yan

et al. 2023

Leukemia Research

View full text Add to dashboard Cite

Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma

Cited by 4 publications

References 26 publications

Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study

Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study

A Novel Prognostic Model for Patients with Primary Gastric Diffuse Large B-Cell Lymphoma

Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL

Contact Info

Product

Resources

About